Myeloproliferative neoplasms (MPN) are a group of related clonal hematological disorders characterized by excess accumulation of one or more myeloid cell lineages and a tendency to transform to acute myeloid leukemia. Deregulated JAK2 signaling has emerged as the central phenotypic driver of BCR-ABL1-negative MPN and a unifying therapeutic target. In addition, MPN show unexpected layers of genetic complexity, with multiple abnormalities associated with disease progression, interactions between inherited factors and phenotype driver mutations, and effects related to the order in which mutations are acquired. Although morphology and clinical laboratory analysis continues to play an important role in defining these conditions, genomic analysis is providing a platform for better disease definition, more accurate diagnosis, direction of therapy and refined prognostication. There is an emerging consensus with regard to many prognostic factors, but a clear need to synthesize genomic findings into robust, clinically actionable and widely accepted scoring systems, and well as the need to standardize the laboratory methodologies that are employed.
Introduction
The World Health Organization classification 1 
Classic BCR-ABL1 negative MPN

Deregulation of JAK2/STAT signalling
Direct or indirect dysregulation of JAK2 signalling by somatically acquired mutations has emerged as a central phenotypic driver of classic MPN. JAK2 is a non-receptor tyrosine kinase which plays an essential role in transducing signals from class 1 cytokine receptors critical for normal myelopoiesis, notably the erythropoietin receptor, the thrombopoietin receptor (TPOR; encoded by the MPL gene) and the granulocyte colony-stimulating factor receptor.
2,3
The principal driver mutations in MPN are indicated on Figure 1 . JAK2 is directly activated by acquisition of the JAK2 V617F mutation, seen in the majority of MPN.
4-7
JAK2 V617F mutation burdens are usually higher in PV and PMF compared to ET, with many cases demonstrating a homozygous mutant clone. 8 Mutations of JAK2 exon 12, typically complex insertion/deletion events, are seen in roughly one third of cases of JAK2 V617F-negative PV. 9 Indirect dysregulation of JAK2 signalling occurs principally by activating mutations in MPL or CALR. MPL mutations are located in exon 10 and most commonly result in amino acid substitutions at W515 of the thrombopoietin receptor (TPOR). 10,11 W515
is located within a small amphipathic motif of the human receptor at the junction between the transmembrane and cytoplasmic domains that is required for maintaining TPOR in its inactive conformation and prevents its autonomous activation; mutation of this residue abrogates this function thereby constitutively activating JAK2 and downstream signalling.
10,12
CALR exon 9 mutations are found in about 25-30% of patients with ET and PMF.
13,14
All pathogenic CALR result in a common frameshift encoding a novel C-terminus with a high positive charge, with 80% of mutants being type-1 (52bp deletion) or type-2 5bp insertion). 13, 14 Calreticulin is a highly conserved chaperone protein that directs the correct conformation and intracellular trafficking of glycoproteins, as well as in homeostatic control of calcium levels. Remarkably, calreticulin mutants specifically activate TPOR, and thereby JAK2, after binding to its extracellular N-glycosylation residues.
15-17
Triple negative MPN ET and PMF negative for standard phenotype driver mutations (JAK2, CALR and MPL) are referred to as 'triple negative'. High throughput sequencing identified noncanonical activating JAK2 or MPL mutations in a minority of triple negative MPN, some of which were somatic but others were inherited, thus identifying cases with hereditary thrombocythemia misdiagnosed as MPN. Similarly, some cases had no evidence for a clonal disorder suggesting that they had also been misdiagnosed. and CBL, respectively, whereas aUPD14q is associated with an imprinting defect.
26-29
Exome sequencing identified a median of 6.5 total somatic mutations in ET and PV, Remarkably, the order in which mutations are acquired is not fixed. In some patients JAK2 V617F is acquired early in the disease and then additional mutations appear as subsequent subclonal events. In other patients, clinically covert clonal hematopoesis is believed to be established by mutations in DNMT3A, TET2 or other abnormalities such as del(20q) or aUPD14q, and JAK2 V617F is acquired as a later event, triggering the onset of an MPN. The order in which mutations are acquired influences the disease phenotype: patients who acquired JAK2 V617F before TET2, DNMT3A or aUPD14q were more likely to develop PV than ET compared to cases where JAK2 V617F was acquired late. 26, 42, 43 In addition, detailed analysis of TET2/JAK2 comutated patients indicated that that the order in which mutations are acquired influences tumor biology as well as the behaviour of stem and progenitor cells.
43
In contrast to JAK2 V617F, CALR mutations show a high degree of clonal dominance throughout hematopoietic development and are believed to be the initiating event in most cases. Additional mutations are thus secondary events associated with disease evolution. 13, 14, 40, 44 The principal genetic abnormalities and evolution of MPN are shown on Figure 2 .
Factors determining disease phenotype
Although MPN phenotype driver mutations all induce the activation of JAK2, they do not lead to the same disorder. JAK2 V617F is associated with PV, ET and PMF while but MPL and CALR mutations are associated with ET and PMF. JAK2 V617F mutant ET patients tend to present many of the phenotypic features of PV and an increased risk of thrombosis compared to ET negative for JAK2 V617F. 45, 46 Cases with MPL mutations are on average older and have higher platelet counts, lower hemoglobin levels and reduced bone marrow cellularity at diagnosis than patients with JAK2 V617F, although, no significant differences in clinical outcome are apparent.
47
CALR mutations in ET are associated with higher platelet counts, lower haemoglobin levels, lower leukocyte counts and younger age at presentation, while the incidence of thrombotic events is lower than JAK2 V617F positive ET. [48] [49] [50] Although no differences in survival have been demonstrated for the different driver mutation subgroups, 50 ET patients with type-1 CALR mutations progress to MF much more frequently than those with type-2 mutations.
51
In PMF the nature of the MPN driver mutation has a stronger prognostic significance.
Compared to JAK2 V617F mutated cases, patients with CALR mutations (most commonly type-1 in PMF) present at a younger age, with higher platelet counts and lower leukocyte counts, but with reduced anemia and transfusion dependency, while they have a better prognosis regarding overall and leukemia-free survival.
Importantly, triple-negative patients for both PMF and post-MPN MF have the worst prognosis and a more severe anemia. 48, 52, 53 Compared to PV and ET, the JAK2 V617F
and CALR mutant allele burden is significantly higher in MF evolving from either ET or PV, indicating a role for the accumulation of mutated alleles in the process of transformation.
48
The reason why some JAK2 V617F positive patients present with PV whereas others present with ET or other myeloid disorders is likely to be multifactorial. As discussed above, the JAK2 mutant allele burden is higher in PV compared to ET and the order in which mutations are acquired can influence the disease phenotype. Constitutional genetics also influences the disease phenotype, with inherited variation in the 
Disease progression and prognostic significance of disease modifying mutations
Considerable effort has been put into the identification of genetic predictors of transformation from MPN to AML. Robust molecular prognostic markers are still lacking for patients with PV and ET, and risk stratification for these patients is still based mainly on clinical criteria and the presence of phenotypic driver mutations.
The mutational burden is certainly higher on transformation of MPN to AML with the appearance of variants in a range of genes that are not unique to MPN but are also seen in other myeloid malignancies ( and ASXL1 appear to be of prognostic significance and correlate with disease progression.
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CSF3R encodes the receptor for granulocyte-colony stimulating factor 3, which requires JAK2 to function. Mutations fall into 2 types: nonsense or frameshift mutations leading to premature truncation of the cytoplasmic tail of the receptor and point mutations in the extracellular domain, most commonly T618I, an abnormality that strongly activates the JAK/STAT signalling. CSF3R mutations are almost always acquired, although a recent report described a child with CNL and an inherited T618I mutation. 92 Ongoing studies are evaluating whether CNL patients are amenable to treatment with JAK2 or other inhibitors, as suggested by initial reports.
88,93
Chronic eosinophilic leukemia and MPN-unclassified A recent study has demonstrated that targeted next-generation sequencing helps to establish clonality in a subset of patients with cytogenetically normal hypereosinophilia that would otherwise have been classified as idiopathic hypereosinophilic syndrome. Importantly, the survival of these cases was significantly shorter than cases without mutations and was indistinguishable from cases with cytogenetically defined CEL, clearly indicating the value of genomic analysis in this disorder. 94 There are no molecular markers for MPN-U but it is possible that wide mutation screens may help to better define this heterogeneous condition.
Concluding remarks
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